Beyond PDL1: OBT has recently discovered a novel T cell modulatory axis, OX001R/L, which is involved in cancer immune escape independent of the PD1/PDL1 axis. "

Press Releases

​2023

Date	Title	Details
09 Mar 2023	Oxford BioTherapeutics  to Announce New Fully Integrated ADC Engine at the World ADC Conference 2023	View here
07 Mar 2023	Oxford BioTherapeutics  wins Tech Company of the Year and Special Recognition Award at Thames Valley SME Growth 100 Awards	View here

​2022

Date	Title	Details
13 June 2022	Oxford BioTherapeutics  enters into Commercial License Agreement with Genmab	View here
13 June 2022	Oxford BioTherapeutics  Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates	View here
27 May 2022	Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022	View here
​25 May 2022	Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in Combination with Agenus CPI Balstilimab	View here
​13 April 2022	Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology target	View here
​07 April 2022	AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076	View here

​2021

Date	Title	Details
20 Sept 2021	Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic	View here
19 Jan 2021	Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics' WuXiBody® Platform	View here
06 Jan 2021	Kite and Oxford BioTherapeutics Establish Cell therapy Research Collaboration in Blood Cancers and Solid Tumours	View here

2020

Date	Title	Details
14 Oct 2020	Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic	View here
09 Jan 2020	Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors ​	View here

2019

Date	Title	Details
25 Jun 2019 ​	Oxford BioTherapeutics Announces Receipt of a Milestone Payment as Boehringer Ingelheim Advances an Oncology Drug Candidate	View here

2018

Date	Title	Details
21 Dec 2018	Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076: An Experimental First in Class ADC Medicine for High Risk Her2 Negative Breast Cancer, Gastric, Lung, Bladder and Ovarian Cancer Patients - US Phase I Clinical Trial to be Initiated	View here
11 Dec 2018	Oxford BioTherapeutics Expands Strategic Collaboration with  WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million	View here
01 Mar 2018	​Oxford BioTherapeutics Appoints Chief Medical Officer, ​Abderrahim Fandi	View here

2017

Date	Title	Details
13 Jun 2017	​Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director	View here
09 Feb 2017	Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans​​​​​	View here
26 Jan 2017	Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics​​	View here

2016

Date	Title	Details
18 Apr 2016	Boehringer Ingelheim Exercises Option on Second Oncology Target using Oxford BioTherapeutics’ OGAP® System​	View here
04 Apr 2016	Oxford BioTherapeutics Licenses Nerviano Medical Sciences’ Drug-Linker Technology to Develop Novel Antibody Drug Conjugates	View here

Media

Immunotherapies Expose and Exploit Cancer’s Varied Weaknesses
March 18 2021: “If we could understand why some people reengage their immune system after receiving chemotherapy, while others don’t, we could think about how to combine various therapeutic modalities and in what sequence”, says Christian Rohlff, PhD, CEO of Oxford BioTherapeutics. Read more here about how OBT uses proprietary immuno-oncology technology and antibody-drug conjugates to develop novel therapeutics that can reengage the immune system to destroy cancer cells.